BRCA2-positive lung adenocarcinoma treated with olaparib: A case report

被引：0

作者：

Motohashi, Takumi ^{[1
]}

Isobe, Kazutoshi ^{[1
,3
]}

Yoshizawa, Takahiro ^{[1
]}

Usui, Yusuke ^{[1
]}

Shimizu, Hiroshige ^{[1
]}

Sekiya, Muneyuki ^{[1
]}

Miyoshi, Shion ^{[1
]}

Nakamura, Yasuhiko ^{[1
]}

Urabe, Naohisa ^{[1
]}

Sakamoto, Susumu ^{[1
]}

Homma, Sakae ^{[1
]}

Sadamoto, Sota ^{[2
]}

Tochigi, Naobumi ^{[2
]}

Kishi, Kazuma ^{[1
]}

机构：

[1] Toho Univ, Sch Med, Div Resp Med, Tokyo, Japan

[2] Toho Univ, Sch Med, Dept Pathol, Tokyo, Japan

[3] Toho Univ, Div Resp Med, Sch Med, Omori nishi 6-11-1,Ota ku, Tokyo 1438541, Japan

来源：

RESPIROLOGY CASE REPORTS | 2024年 / 12卷 / 03期

关键词：

adenocarcinoma; BRCA2 gene mutation; cancer genomic profiling test; olaparib;

D O I：

10.1002/rcr2.1317

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

A 66-year-old woman was found to have abnormal shadows on a chest radiograph at a previous hospital 4 years ago, which led to a diagnosis of lung adenocarcinoma, cT2aN1M1b stage IVA. First-line treatment included carboplatin and paclitaxel plus thoracic radiotherapy and stereotactic radiation therapy for brain metastases. The patient later underwent second-line pemetrexed treatment, followed by third-line nivolumab, fourth-line docetaxel and bevacizumab, fifth-line tegafur-gimeracil-oteracil, and sixth-line gemcitabine. Two years ago, after observing an increase in the primary lesion and carcinoembryonic antigen levels (104.0 ng/mL), a computed tomography-guided biopsy was performed from the primary site of lung cancer. A cancer genomic profiling test (FoundationOne (R) CDx cancer genome profile) revealed a breast cancer susceptibility (BRCA) 2 gene mutation. Therefore, she started taking olaparib. The treatment led to stable disease for approximately 2 years.

引用

页数：4

共 4 条

[1] Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients [J].

Hu, Xingsheng ;

Yang, Dongyong ;

Li, Yalun ;

Li, Li ;

Wang, Yan ;

Chen, Peng ;

Xu, Song ;

Pu, Xingxiang ;

Zhu, Wei ;

Deng, Pengbo ;

Yen, Junyi ;

Zhang, Hanhan ;

Lizaso, Analyn ;

Liu, Hao ;

Mao, Xinru ;

Huang, Hai ;

Chu, Qian ;

Hu, Chengping .

CANCER BIOLOGY & MEDICINE, 2019, 16 (03) :556-564

[2] Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial [J].

Remon, Jordi ;

Besse, Benjamin ;

Leary, Alexandra ;

Bieche, Ivan ;

Job, Bastien ;

Lacroix, Ludovic ;

Auguste, Aurelie ;

Mauduit, Marjorie ;

Audigier-Valette, Clarisse ;

Raimbourg, Judith ;

Madroszyk, Anne ;

Michels, Stefan ;

Bayar, Mohammed Amine ;

Jimenez, Marta ;

Soria, Jean-Charles ;

Rouleau, Etienne ;

Barlesi, Fabrice .

JTO CLINICAL AND RESEARCH REPORTS, 2020, 1 (03)

[3] Characterization of lung cancers in patients with BRCA germline variants: A multicenter series [J].

Sanchis-Borja, Mateo ;

Fallet, Vincent ;

Fabre, Elisabeth ;

Wislez, Marie ;

Culine, Stephane ;

Zalcman, Gerard ;

Spano, Jean-Philippe ;

Buffet, Nathalie Chabbert ;

Coulet, Florence ;

Benusiglio, Patrick R. ;

Cadranel, Jacques .

LUNG CANCER, 2022, 173 :67-70

[4] Spectrum of Pathogenic Germline Mutations in Chinese Lung Cancer Patients through Next-Generation Sequencing [J].

Tian, Panwen ;

Cheng, Xiangyang ;

Zhao, Zhengyi ;

Zhang, Yuzi ;

Bao, Celimuge ;

Wang, Yanyan ;

Cai, Shangli ;

Ma, Guowei ;

Huang, Ying .

PATHOLOGY & ONCOLOGY RESEARCH, 2020, 26 (01) :109-114

← 1 →